Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) (NCT02864992) | EMD Serono Research & Development Institute, Inc. | 2016-09-13 |
Track Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification automatically
Every clearance here is in the API, with alerts when new ones post.